- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

When the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring (CGM) system in September 2017, diabetes advocates hailed the move as long overdue and one that might lead to greater ...

"FreeStyle Libre technology was designed from the start to be affordable and accessible," said Jared Watkin, senior vice president for Abbott's diabetes care business. "We've been focused on ...

Cost model data published in U.S. Endocrinology show for commercially-insured people with diabetes on intensive insulin therapy, using FreeStyle Libre technology costs 60% less compared to traditional ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA granted clearance for a standalone reader to be ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...